AVP-923 Study (H-31623)
Description: Baylor College of Medicine is one of about 25 sites in the U.S. participating in this trial. The purpose of this study is to determine if a drug which has been approved to treat uncontrolled emotions in people with diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and dementia is also effective in treating agitation in people with Alzheimer's disease.
Eligibility: Men and women between 50 and 90 years of age in general good physical health with mild to severe stage Alzheimer's disease who have had agitation for at least the past seven days. They must also have a reliable caregiver who can accompany them to eight study visits over a 12-week period and can answer questions about their memory and behavior.
For more information contact Elizabeth Lipscomb, R.N. at (713) 798-7431 or email email@example.com.